Before starting an IV drip, a healthcare professional will assess the patient’s condition and determine the type of solution ...

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announced the nationwide rollout of its ...

The home infusion industry is experiencing significant growth due to the increasing number of aging patients wanting to ...

Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...

Leqembi is approved for Alzheimer’s patients in multiple territories, but questions remain over its cost-effectiveness.

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for ...

The Quadruple Aim—a framework originally rooted in improving patient experience, enhancing population health, and achieving ...

This spring, a few days after his 2nd birthday, Brigland Pfeffer was playing with his siblings in their San Diego backyard.

Onchilles Pharma has leveraged this pathway to develop N17350 and NEU-002, two leading therapeutic candidates designed for intratumoral and intravenous (IV) administration ... as potential ...

The anticipated impact of hurricanes and an intravenous (IV) shortage may result in softer sales for the ... solutions for patients with obstructive sleep apnea. It offers inspire therapy, which ...

His treatment, developed with David Nalin, was elegant in its simplicity, which made it accessible to people and countries ...

Antivenom, an antibody therapy that disables certain toxins, is usually administered via an intravenous line, directly into ...